Liu SY, Wang D, Liu J, Yang LP, Chen GY. Influence of nonalcoholic fatty liver disease on response to antiviral treatment in patients with chronic hepatitis B: A meta-analysis. World J Hepatol 2024; 16(3): 465-476 [PMID: 38577526 DOI: 10.4254/wjh.v16.i3.465]
Corresponding Author of This Article
Gong-Ying Chen, MD, Professor, Department of Infectious and Hepatology Diseases, Affiliated Hospital of Hangzhou Normal University, No. 126 Wenzhou Road, Hangzhou 310015, Zhejiang Province, China. liuxingli0329@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Shi-Yi Liu, Lu-Ping Yang, Department of Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang Province, China
Dian Wang, Department of Medicine, Hangzhou Normal University, Hangzhou 310011, Zhejiang Province, China
Jing Liu, Gong-Ying Chen, Department of Infectious and Hepatology Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou 310015, Zhejiang Province, China
Co-first authors: Shi-Yi Liu and Dian Wang.
Author contributions: Liu SY and Wang D reviewed each article independently; Data were extracted from studies meeting both inclusion and exclusion criteria following a review of the entire contents of each paper; Chen GY as a third investigator, discussion, or revision to resolve any differences.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gong-Ying Chen, MD, Professor, Department of Infectious and Hepatology Diseases, Affiliated Hospital of Hangzhou Normal University, No. 126 Wenzhou Road, Hangzhou 310015, Zhejiang Province, China. liuxingli0329@163.com
Received: October 24, 2023 Peer-review started: October 24, 2023 First decision: January 5, 2024 Revised: January 26, 2024 Accepted: February 28, 2024 Article in press: February 28, 2024 Published online: March 27, 2024 Processing time: 155 Days and 3.3 Hours
Abstract
BACKGROUND
Although hepatitis B virus infection is the leading cause of chronic liver injury globally, nonalcoholic fatty liver disease (NAFLD) is gradually gaining attention as another major chronic liver disease. The number of patients having chronic hepatitis B (CHB) with concomitant hepatic steatosis has increased.
AIM
To analyze the effect of NAFLD on the response to antiviral treatment in patients with CHB.
METHODS
Relevant English studies were systematically searched across PubMed, EMBASE, Web of Science, and Cochrane Library until October 2023. Studies in which the treatment outcomes were compared between patients with CHB only and those with CHB and hepatic steatosis were included.
RESULTS
Of the 2502 retrieved studies, 11 articles were finally included. Biochemical response until 48 wk (OR = 0.87, 95%CI: 0.50–1.53, P = 0.000) and 96 wk (OR = 0.35, 95%CI: 0.24–0.53, P = 0.24) and virological response until 96 wk (OR = 0.80, 95%CI: 0.43–1.49, P = 0.097) were lower in patients with hepatic steatosis than in patients with CHB alone.
CONCLUSION
Hepatic steatosis lowers the biochemical response to antiviral treatment in patients with CHB.
Core Tip: No consensus is available in the literature about which effect of nonalcoholic fatty liver disease on the response to antiviral treatment in patients with chronic hepatitis B (CHB). This is a systematic review and meta-analysis comparing the response to antiviral treatment between patients with CHB only and those with CHB and hepatic steatosis were included. We investigated these two groups in terms of biochemical responses, serological responses, virological responses the incidence of hepatocellular carcinoma.
